Genetics of bleeding disorders in women

Seminars in Thrombosis and Hemostasis

Volumn 34, Issue 6, 2008, Pages 509-519

  Novelli, Enrico M ^a   Ragni, Margaret V ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Hemophilia Center of Western PA   (United States)

Author keywords

Bleeding disorders; Bleeding severity score; Genetic testing; Genotype; Menorrhagia; VWD

Indexed keywords

DESMOPRESSIN; ORAL CONTRACEPTIVE AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 8;

BERNARD SOULIER DISEASE; BLEEDING DISORDER; BLOOD CLOTTING FACTOR 11 DEFICIENCY; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; EHLERS DANLOS SYNDROME; GENE MUTATION; GLANZMANN DISEASE; HEMOPHILIA A; HEMOPHILIA B; HUMAN; MENORRHAGIA; PHENOTYPE; PREMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; RENDU OSLER WEBER DISEASE; REVIEW; THROMBOCYTE TRANSFUSION; VON WILLEBRAND DISEASE;

BLOOD COAGULATION DISORDERS; BLOOD COAGULATION FACTORS; BLOOD PLATELET DISORDERS; DIAGNOSIS, DIFFERENTIAL; EHLERS-DANLOS SYNDROME; FEMALE; HEMORRHAGE; HUMANS; MUTATION; PLATELET TRANSFUSION; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; VON WILLEBRAND DISEASE;

EID: 57149083278     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0028-1103362     Document Type: Review

References (80)

1. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987;69:454-459
2. Mancuso DJ, Tuley EA, Westfield LA, et al. Structure of the gene for human von Willebrand factor. J Biol Chem 1989;264:19514-19527
3. Sadler JE, Budde U, Eikenboom JC, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006;4:2103-2114
4. James AH. More than menorrhagia: a review of the obstetric and gynaecological manifestations of von Willebrand disease. Thromb Res 2007;120(Suppl 1):S17-S20
5. James PD, Notley C, Hegadorn C, et al. The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood 2007;109:145-154
6. Goodeve A, Eikenboom J, Castaman G, et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood 2007;109:112-121
7. Bellissimo DB, Christopherson PA, Haberichter SL, et al. Novel VWF sequence variations identified in normal controls and index cases enrolled in the TS Zimmerman Program for the Molecular and Clinical Biology of VWD (ZPMCB-VWD). Blood 2007;110:709 (a218)
8. Rodeghiero F, Castaman G, Tosetto A, et al. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. [see comment] [erratum appears in J Thromb Haemost 2006;4(4):925] J Thromb Haemost 2005;3:2619-2626
9. Haberichter SL, Christopherson PA, Perry CL, et al. The prevalence of reduced VWF survival phenotype (type 1C VWD) in type 1 index cases recruited into the TS Zimmerman Program for the Molecular and Clinical Biology of VWD (ZPMCB - VWD). Blood 2007;110:2133 (a635)
10. Eikenboom J, Van Marion V, Putter H, et al. Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD. J Thromb Haemost 2006;4:774-782
11. Casana P, Cabrera N, Haya S, Cid AR, Aznar JA. Von Willebrand's disease: a novel mutation, P1824H and the incidence of R1205H defect among families with dominant quantitative von Willebrand factor deficiency. Haematologica 2006;91:1130-1133
12. Bowen DJ, Collins PW. An amino acid polymorphism in von Willebrand factor correlates with increased susceptibility to proteolysis by ADAMTS13. Blood 2004;103:941-947
13. Cumming A, Grundy P, Keeney S, et al. An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease. Thromb Haemost 2006;96:630-641
14. Goodeve A. Genetics of type 1 von Willebrand disease. Curr Opin Hematol 2007;14:444-449
15. Flood VH, Kautza BC, Miller CA, et al. Common VWF haplotypes in normal African-Americans and Caucasians recruited into the ZPMCB-VWD and their impact on VWF laboratory testing. Blood 2007;110:714 (a219)
16. Casonato A, Sartorello F, Pontara E, et al. A novel von Willebrand factor mutation (I1372S) associated with type 2B-like von Willebrand disease: an elusive phenotype and a difficult diagnosis. Thromb Haemost 2007;98:1182-1187
17. Eikenboom JC. Congenital von Willebrand disease type 3: clinical manifestations, pathophysiology and molecular biology. Best Pract Res Clin Haematol 2001;14:365-379
18. von Willebrand EA. Hereditary pseudohaemophilia. Haemophilia 1999;5:223-231discussion 222
19. Zhang ZP, Blomback M, Nyman D, Anvret M. Mutations of von Willebrand factor gene in families with von Willebrand disease in the Åland Islands. Proc Natl Acad Sci U S A 1993;90:7937-7940
20. Baronciani L, Cozzi G, Canciani MT, et al. Molecular defects in type 3 von Willebrand disease: updated results from 40 multiethnic patients. Blood Cells Mol Dis 2003;30:264-270
21. Ragni MV, Bontempo FA, Hassett AC. von Willebrand disease and bleeding in women. Haemophilia 1999;5:313-317
22. James AH, Ragni MV, Picozzi VJ. Bleeding disorders in premenopausal women: (another) public health crisis for hematology? Hematology Am Soc Hematol Educ Program 2006:474-485
23. Sadler JE. Von Willebrand disease type 1: a diagnosis in search of a disease. Blood 2003;101:2089-2093
24. Goldberg L, Ragni M. Bleeding score as a preoperative predictor of postoperative bleeding in type 1 von Willebrand disease. Blood 2006;4394: (303a)
25. Federici AB, Castaman G, Thompson A, Berntorp E. Von Willebrand's disease: clinical management. Haemophilia 2006;12(Suppl 3):152-158
26. Tosetto A, Rodeghiero F, Castaman G, et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006;4:766-773
27. Tosetto A, Castaman G, Rodeghiero F. Assessing bleeding in von Willebrand disease with bleeding score. Blood Rev 2007;21:89-97
28. Tosetto A, Castaman G, Rodeghiero F. Evidence-based diagnosis of type 1 von Willebrand disease: a Bayes theorem approach. Blood 2008;111:3998-4003
29. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 1997;90:2515-2521
30. Mannucci PM. Treatment of von Willebrand's disease. N Engl J Med 2004;351:683-694
31. Petitti DB. Clinical practice. Combination estrogen-progestin oral contraceptives. N Engl J Med 2003;349:1443-1450
32. Kadir RA, Lee CA, Sabin CA, Pollard D, Economides DL. DDAVP nasal spray for treatment of menorrhagia in women with inherited bleeding disorders: a randomized placebo-controlled crossover study. Haemophilia 2002;8:787-793
33. Castaman G, Lethagen S, Federici AB, et al. Response to desmopressin is influenced by the genotype and phenotype in type 1 Von Willebrand Disease (VWD): results from the European study MCMDM-1VWD. Blood 2008;111:3531-3539
34. Mannucci PM. Use of desmopressin (DDAVP) during early pregnancy in factor VIII-deficient women. Blood 2005;105:3382
35. Thompson AR, Gill JC, Ewenstein BM, Mueller-Velten G, Schwartz BA. Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate-P). Haemophilia 2004;10:42-51
36. Jankowitz R, Nichols T, Ragni M. Recombinant IL-11 (Neumega, rhIL-11) increases plasma von Willebrand factor in type 1 von Willebrand disease. Blood 2006;108:1003 (299a)
37. Denis CV, Kwack K, Saffaripour S, et al. Interleukin 11 significantly increases plasma von Willebrand factor and factor VIII in wild type and von Willebrand disease mouse models. Blood 2001;97:465-472
38. Aydinok Y, Egemen A, Balkan C. Menorrhagia due to abnormalities of the platelet function: evaluation of two young patients. Pediatr Int 2007;49:106-108
39. Rosenberg N, Lalezari S, Landau M, Shenkman B, Seligsohn U, Izraeli S. Trp207Gly in platelet glycoprotein Ib alpha is a novel mutation that disrupts the connection between the leucine-rich repeat domain and the disulfide loop structure and causes Bernard-Soulier syndrome. J Thromb Haemost 2007;5:378-386
40. Kenny D, Morateck PA, Gill JC, Montgomery RR. The critical interaction of glycoprotein (GP) IB beta with GPIX-a genetic cause of Bernard-Soulier syndrome. Blood 1999;93:2968-2975
41. Miller JL. Platelet-type von Willebrand disease. Thromb Haemost 1996;75:865-869
42. Franchini M, Montagnana M, Lippi G. Clinical, laboratory and therapeutic aspects of platelet-type von Willebrand disease. Int J Lab Hematol 2008;30:91-94
43. Takafuta T, Fujimura K, Shimomura T, et al. Precise diagnosis by gene analysis and successful management of delivery in three patients with type IIB von Willebrand disease. Int J Hematol 1994;60:163-172
44. Gohda F, Uchiumi H, Handa H, et al. Identification of inherited macrothrombocytopenias based on mean platelet volume among patients diagnosed with idiopathic thrombocytopenia. Thromb Res 2007;119:741-746
45. Poon M-C. Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann's thrombasthenia. Vasc Health Risk Manag 2007;3:655-664
46. Anwer A, Hanley J, Kumarendran K. Proposed management of pregnancy and labour in an inherited platelet disorder, Glanzmann's thrombasthenia. J Obstet Gynaecol 2007;27:421-423
47. Poddar RK, Coley S, Pavord S. Hermansky-Pudlak syndrome in a pregnant patient. Br J Anaesth 2004;93:740-742
48. Haldane JBS, Waddington CH. Inbreeding and linkage. Genetics 1931;16:357-374
49. Yang MY, Ragni MV. Clinical manifestations and management of labor and delivery in women with factor IX deficiency. Haemophilia 2004;10:483-490
50. Acquila M, Caprino D, Bicocchi P, Mori PG, Tagliaferri AR. A skewed lyonization phenomenon as cause of hemophilia A in a female patient. Blood 1995;85:599-600
51. Kadir RA, Economides DL, Braithwaite J, Goldman E, Lee CA. The obstetric experience of carriers of haemophilia. Br J Obstet Gynaecol 1997;104:803-810
52. Leissinger C, Becton D, Cornell CJr, ,Cox Gill J. High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia 2001;7:258-266
53. Gekas J, Broermann L, Heidenreich W. Outcome of pregnancy in patients with haemophilia B - two case reports. Z Geburtshilfe Neonatol 2007;211:90-92
54. Shpilberg O, Peretz H, Zivelin A, et al. One of the two common mutations causing factor XI deficiency in Ashkenazi Jews (type II) is also prevalent in Iraqi Jews, who represent the ancient gene pool of Jews. Blood 1995;85:429-432
55. Ragni MV, Sinha D, Seaman F, Lewis JH, Spero JA, Walsh PN. Comparison of bleeding tendency, factor XI coagulant activity, and factor XI antigen in 25 factor XI-deficient kindreds. Blood 1985;65:719-724
56. Bolton-Maggs PH. Bleeding problems in factor XI deficient women. Haemophilia 1999;5:155-159
57. White B, Lawler P, Riddell A, et al. Response to desmopressin of factors XI, X and V in patients with factor VIII deficiency and von Willebrand disease. Br J Haematol 2004;126:100-104
58. Franchini M, de Gironcoli M, Lippi G, Manzato F, Aprili G, Gandini G. Prophylactic use of desmopressin in surgery of six patients with symptomatic heterozygous factor XI deficiency. Haematologica 2000;85:106-107
59. Mavromatidis G, Dinas K, Delkos D, et al. Uneventful cesarean delivery with administration of factor XI concentrate in a patient with severe factor XI deficiency. Int J Hematol 2007;86:222-224
60. Bern MM, Sahud M, Zhukov O, Qu K, Mitchell WJr. Treatment of factor XI inhibitor using recombinant activated factor VIIa. Haemophilia 2005;11:20-25
61. Peyvandi F, Jayandharan G, Chandy M, et al. Genetic diagnosis of haemophilia and other inherited bleeding disorders. Haemophilia 2006;12(Suppl 3):82-89
62. Catanzarite VA, Novotny WF, Cousins LM, Schneider JM. Pregnancies in a patient with congenital absence of prothrombin activity: case report. Am J Perinatol 1997;14: 135-138
63. Girolami A, Scarano L, Saggiorato G, Girolami B, Bertomoro A, Marchiori A. Congenital deficiencies and abnormalities of prothrombin. Blood Coagul Fibrinolysis 1998;9:557-569
64. Vellinga S, Steel E, Vangenechten I, Gadisseur A. Successful pregnancy in a patient with factor V deficiency: case report and review of the literature. Thromb Haemost 2006;95:896-897
65. Girolami A, Scandellari R, Lombardi AM, Girolami B, Bortoletto E, Zanon E. Pregnancy and oral contraceptives in factor V deficiency: a study of 22 patients (five homozygotes and 17 heterozygotes) and review of the literature. Haemophilia 2005;11:26-30
66. D'Ambrosio R, Santacroce R, Di Perna P, Sarno M, Romondia A, Margaglione M. A new case of combined factor V and factor VIII deficiency further suggests that the LMAN1 M1T mutation is a frequent cause in Italian patients. Blood Coagul Fibrinolysis 2007;18:203-204
67. Mohanty D, Ghosh K, Shetty S, Spreafico M, Garagiola I, Peyvandi F. Mutations in the MCFD2 gene and a novel mutation in the LMAN1 gene in Indian families with combined deficiency of factor V and VIII. Am J Hematol 2005;79:262-266
68. Fregin A, Rost S, Wolz W, Krebsova A, Muller CR, Oldenburg J. Homozygosity mapping of a second gene locus for hereditary combined deficiency of vitamin K-dependent clotting factors to the centromeric region of chromosome 16. Blood 2002;100:3229-3232
69. Zhang B, Ginsburg D. Familial multiple coagulation factor deficiencies: new biologic insight from rare genetic bleeding disorders. J Thromb Haemost 2004;2:1564-1572
70. Johnson DW, Berg JN, Gallione CJ, et al. A second locus for hereditary hemorrhagic telangiectasia maps to chromosome 12. Genome Res 1995;5:21-28
71. McAllister KA, Grogg KM, Johnson DW, et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994;8:345-351
72. Lesca G, Olivieri C, Burnichon N, et al. Genotype-phenotype correlations in hereditary hemorrhagic telangiectasia: data from the French-Italian HHT network. Genet Med 2007;9:14-22
73. Letteboer TG, Mager JJ, Snijder RJ, et al. Genotype-phenotype relationship in hereditary haemorrhagic telangiectasia. J Med Genet 2006;43:371-377
74. Dahlgren LS, Effer SB, McGillivray BC, Pugash DJ. Pregnancy with uterine vascular malformations associated with hemorrhagic hereditary telangiectasia: a case report. J Obstet Gynaecol Can 2006;28:720-723
75. Worda C, Lang I, Husslein P, Kneussl M. Hereditary hemorrhagic telangiectasia and pregnancy. Obstet Gynecol 2007;110:474-477
76. Cottin V, Chinet T, Lavole A, et al. Pulmonary arteriovenous malformations in hereditary hemorrhagic telangiectasia: a series of 126 patients. Medicine 2007;86:1-17
77. Pepin M, Schwarze U, Superti-Furga A, Byers PH. Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type. N Engl J Med 2000;342:673-680
78. Bjorck M, Pigg M, Kragsterman B, Bergqvist D. Fatal bleeding following delivery: a manifestation of the vascular type of Ehlers-Danlos' syndrome. Gynecol Obstet Invest 2007;63:173-175
79. Volkov N, Nisenblat V, Ohel G, Gonen R. Ehlers-Danlos syndrome: insights on obstetric aspects. Obstet Gynecol Surv 2007;62:51-57
80. Pallotta R, Ehresmann T, Fusilli P, De Paepe A, Nuytinck L. Discordance between phenotypic appearance and genotypic findings in a familial case of classical Ehlers-Danlos syndrome. Am J Med Genet A 2004;128A:436-438